Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Sells 22,996 Shares of Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) major shareholder Portage Biotech Inc. sold 22,996 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $30.03, for a total transaction of $690,569.88. Following the completion of the transaction, the insider now owns 6,278,504 shares in the company, valued at approximately $188,543,475.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Portage Biotech Inc. also recently made the following trade(s):

  • On Tuesday, January 9th, Portage Biotech Inc. sold 84,881 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.06, for a total transaction of $2,551,522.86.
  • On Wednesday, January 3rd, Portage Biotech Inc. sold 35,650 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $28.61, for a total transaction of $1,019,946.50.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) opened at $26.13 on Friday. The stock has a market cap of $975.72 and a P/E ratio of -5.01. Biohaven Pharmaceutical Holding Co Ltd has a 1 year low of $17.00 and a 1 year high of $39.51.

Several institutional investors have recently added to or reduced their stakes in BHVN. VHCP Management II LLC acquired a new position in shares of Biohaven Pharmaceutical during the 3rd quarter valued at $60,826,000. Eagle Asset Management Inc. acquired a new position in shares of Biohaven Pharmaceutical during the 3rd quarter valued at $32,635,000. Janus Henderson Group PLC acquired a new position in shares of Biohaven Pharmaceutical during the 3rd quarter valued at $25,751,000. JPMorgan Chase & Co. acquired a new position in shares of Biohaven Pharmaceutical during the 3rd quarter valued at $18,173,000. Finally, Stifel Financial Corp acquired a new position in shares of Biohaven Pharmaceutical during the 3rd quarter valued at $15,525,000. Institutional investors own 47.76% of the company’s stock.

A number of brokerages have recently issued reports on BHVN. BidaskClub upgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 28th. Morgan Stanley boosted their price target on shares of Biohaven Pharmaceutical from $28.00 to $47.00 and gave the stock an “overweight” rating in a research report on Monday, September 25th. William Blair restated an “outperform” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. Needham & Company LLC dropped their price target on shares of Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, October 3rd. Finally, Zacks Investment Research upgraded shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $36.14.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Sells 22,996 Shares of Stock” was first published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.themarketsdaily.com/2018/01/12/insider-selling-biohaven-pharmaceutical-holding-co-ltd-bhvn-major-shareholder-sells-22996-shares-of-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply